We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Screening Assay Approved in China and Brazil

By LabMedica International staff writers
Posted on 18 Nov 2010
An assay used in markets around the globe to screen donated blood for human immunodeficiency virus (HIV) Type 1 and Hepatitis viruses types B and C, has been granted approval for use in China and Brazil.

Sensitivity combined with the fully integrated and automated Procleix Ultrio assay, which is run on the TIGRIS platform, simplifies workflow and improves efficiency in the lab, a critical component to ensure testing and results are completed on time.

Novartis Diagnostics (Basel, Switzerland) launched the Procleix Ultrio assay and the Procleix TIGRIS platform in China at the Chinese Society of Blood Transfusion (CSBT) meeting, which took place on November 4-6, 2010, in Chengdu, China. More...
In Brazil, Novartis featured the Procleix Ultrio assay and the Procleix TIGRIS platform during the HEMO-Brazil meeting, which took place November 5-8, 2010, in Brasilia.

The company is working closely with blood centers in China and Brazil to introduce Ultrio and TIGRIS and help add an additional layer of blood safety to the blood screening process. In China, Novartis Diagnostics is collaborating with the Ministry of Health as part of the 2010 China nucleic acid testing (NAT) pilot program, sharing knowledge and best practices with blood centers using the Procleix Ultrio and TIGRIS systems to test NAT in their blood centers.

Blood screening centers in China and Brazil currently receive 10 million and 4.3 million annual blood donations, respectively. Blood centers in both countries are incorporating additional layers of protection to the blood screening process to increase the safety of the blood supply from donor to patient.

Related Links:

Novartis Diagnostics





Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.